Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The dept. of Anesthesiology currently has a database of subjects whom had surgery and
received either Aprotinin or Amicar in the OR. The current viewpoint is that Aprotinin is
more harmful than Amicard. In an effort to see what the long term outcomes were for subjects
whom had surgery here at Upstate, it was decided to look at long term death rates to see if
any differences. A student t-test will be used to determine statistical significance where a
p value of <0.05 will be deemed significant. Using data from 462 subjects that had undergone
cardiac surgery at SUNY Upstate Medical University, CABG only and the long term mortality
rate from the Mangano, et.al. publications, the unadjusted mortality for the two drugs are
Aprotinin 5.4% and Amicar 1.2%. A power analysis was performed using the hospital mortality
rates of 5.4% and 1.2% with the sample size in the propensity data and a p-value of 0.05. The
result was a power of 81.7%.
Details
Lead Sponsor:
State University of New York - Upstate Medical University